twitter logo linkedin logo facebook logo youtube logo instagram logo search icon star icon United Kingdom Flag Netherlands Flag Germany Flag France Flag Italy Flag Switzerland Flag Canada Flag Belgium Flag Denmark Flag Finland Flag Greece Flag Ireland Flag Sweden Flag Portugal Flag Spain Flag Skip to content
  • Language
    • English
    • Deutsch
    • Français
    • Español
    • Italiano
  • Schweizer Angebot
  • Dienstleistungen
  • Therapeutische Bereiche
  • Über uns
    • Über uns
    • Unsere Standorte
    • Führungsteam
    • Lernen Sie unsere Spezialisten kennen
  • Wissenszentrum
  • Deutsch
    • English
    • Deutsch
    • Français
    • Español
    • Italiano
  • Schweizer Angebot
  • Globales Angebot
  • Language
    • English
    • Deutsch
    • Français
    • Español
    • Italiano
  • Schweizer Angebot
  • Dienstleistungen
  • Therapeutische Bereiche
  • Über uns
    • Über uns
    • Unsere Standorte
    • Führungsteam
    • Lernen Sie unsere Spezialisten kennen
  • Wissenszentrum
Kontakt
  • Home
  • Wissensdrehscheibe
  • Rare diseases

Rare diseases

Expansion into new international biotech markets can be challenging. Unfamiliar regulations and licensing, coupled with language and cultural differences, can all be barriers to growth. If you’re considering venturing into Europe and beyond, our easy-to-follow guides, shaped by 30 years of expertise in the rare disease market, will assist you in navigating challenges and gaining a profound understanding of the complexities involved in launching orphan drugs into new markets. To learn more about how Sciensus can facilitate and support your Europan expansion, visit: Rare Diseases and Orphan Drugs

or

View all
Expanded Access Programs

Blogs

Rare diseases

EMA orphan drug designation

real-world data

Blogs

Rare diseases

Four considerations before collecting real-world data in your EAP

rare and speciality diseases

Blogs

Rare diseases

The increasing importance of real-world data for the EMA

Real-world data

Blogs

Rare diseases

Real-world data and shaping the future of healthcare 

early access program benefits

Blogs

Rare diseases

Six steps for a successful Early Access Program in Europe 

patient support program in europe

Thought Leadership

Rare diseases

Get the free whitepaper: Transitioning from open-label extensions to early access programs

orphan drug development

Blogs

Rare diseases

Mitigating risks in early access programmes: A guide for biotech companies

Boys playing football

Thought Leadership

Rare diseases

Get the free whitepaper: How early access programs & real-world data help Biotechs succeed

medicine adherence

News

Rare diseases

Sciensus partners with Sentynl Therapeutics

  • Previous results
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • Next results

Sciensus kontaktieren

Wenn Sie Fragen haben oder mehr über unsere Arbeit erfahren möchten, gehen Sie bitte zur Seite „Kontakt“, um mit uns in Verbindung zu treten.

Kontakt
Registered Pharmacies

Fifth Avenue, Centrum 100, Burton-on-Trent, Staffordshire, DE14 2WS, UK

General Pharmaceutical Council Registration 1084907

Plot 7, Junction Close, Green Lane Industrial Park, Featherstone, Pontefract, West Yorkshire, WF7 6ER, UK

General Pharmaceutical
Council Registration 1092334

Twitter logo Linkedin logo Facebook logo Youtube logo
  • Datenschutzhinweise
  • Allgemeine Geschäftsbedingungen

©2025 - Sciensus | All rights reserved